DMRA

Damora Therapeutics Stock Analysis

AI Rating

Good
  • Quality3/10
  • Growth↑ 7/10
  • Value↓ 4/10
Damora Therapeutics sales and earnings growth
DMRA Growth
Good
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 37.09%
  • FCF Y/Y↑ 51.24%
Damora Therapeutics gross and profit margin trends
DMRA Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ 1.75%
Damora Therapeutics net debt vs free cash flow
DMRA Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Damora Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗